Clinical Trial Development Award

University of Illinois Cancer Center: Investigator Initiated Therapeutic Clinical Trial Development Award

Clinical Trial Development Award

The goals of the Cancer Center Therapeutic Clinical Trial Development Award Program are to foster innovative therapeutic clinical trials to benefit UI Cancer Center oncology patients. The total amount of the grant is up to $250,000. Only direct costs of the research are supported by this award.

Application Criteria

The following criteria are applicable:

  • The project must be a new therapeutic clinical trial directed at UI Health oncology patients.
  • Only cancer-focused studies with high scientific merit will be considered.
  • Applicants must be paid UIC faculty
  • Projects are for one (1) year with an option to renew, if applicable, for an additional year of funding contingent upon evidence of significant progress during Year 1 and available funding.
  • Only single center clinical trials conducted at UIC will be considered.
  • Preference for applications that enroll a significant number of patients in a disease area of particular high incidence in the UI Cancer Center patient population and/or addresses a significant therapeutic need for the UI Cancer Center oncology patient population.
  • Preference is given for industry partnerships and proposals with a high likelihood of generating future NIH extramural funding

Phase 1

Please complete the online application The application requires a 2-page competitive Letter of Intent (LOI). The LOI should have 0.5” margins and no smaller than Arial 11 point font. It is due by 5 PM on May 20th, 2019.

The following information should be included:

  • Title page
  • Brief outline of the study plan (goal, hypothesis, specific aims, study methods to be utilized) 1 page.
  • Complete listing of the investigative team, academic titles, primary departments, and roles 1 page.
  • Biosketches and Other Support documentation for Principal Investigators and Project Leaders.

All LOIs will be reviewed by a review committee appointed by the UI Cancer Center Director who have no conflict of interest related to the proposal and/or PIs. Those who submit an LOI will be notified by May 24th, 2019 if they are invited to submit a full application (Phase 2)

Phase 2

To submit a full application for the Therapeutic Clinical Trial Development Award: Please scan and upload a single PDF file that contains the following:

  • Application Format: Use standard 11-point font, single space, and half-inch margins throughout the application. Consecutively number all pages.
  • Face Page: Complete Face Page form (not included in the 5 page limit). Download at: Face Page Form
  • Research Plans for Each Project (limit 5 pages):
    • Specific Aims: State concisely the hypothesis to be tested and the specific aim(s) to be achieved during the one year
    • Research Strategy
      • Significance
      • Innovation
      • Approach
    • Timeline: A detailed project timeline with project milestones identified.

In addition, as part of the scientific peer review, all applications will be evaluated on scientific and technical merit, as well as feasibility.


  • Budget:Use PHS 398 from page 4 ( followed by a written budget justification. The budget cap is $250,000 direct costs. Include direct costs only; there are no indirect costs associated with this grant. No faculty salaries should be included. Any faculty effort related to this award must be listed and supported by the respective department as cost share. By signing the cover page, the departmental business managers verify and approve this cost share. Salary support for laboratory personnel, post-doctoral fellows, etc. may be included. Study management services, including regulatory services, data management, and study coordination, will be provided by the Cancer Center Clinical Trials Office (CTO). Costs for these activities do not need to be included in the budget. Include justification for all budget requests. Budgets should only include monies to be spent; include a separate page to describe the collaborators and their roles on the project. Note: effort for each faculty team member must be articulated with a written commitment of departmental support for that effort. Every budgeted item must be classified into a category (e.g., supplies, patient care costs) with unit costs specified and defined. Equipment costing over $5,000 is not allowed. Travel expenses will only be allowed when necessary to carry out the proposed research project. The cancer center reserves the right to reduce award amounts.
  • Description of RRC or Other Cores (limit 1 page total): Include a description of how each core will support projects, if applicable.
  • Literature Cited: select only those references pertinent to the proposed research.
  • List of Collaborative Publications from the Research Team.
  • Description of How Program Milestones Will be achieved.
  • Biosketches: Biosketches for all faculty team investigators must be Personal statements must include the specific role of each team member.
  • Funding: Up to $250, 000 total costs. 1 will be awarded. Funds will be released upon IRB approval only.
  • Deadlines: Full application due June 21, 2019. Notifications of awards will be made by July 8, 2019.

Submission: Please scan and upload full application here:

Award Details

One award will be made on a competitive basis for a maximum of $250,000. The maximum period of the award is 24 months. Awardees are required to submit brief quarterly progress reports and a final progress report upon project completion. If timely progress is not made throughout the award year, the award can be terminated upon consultation of the Cancer Center Executive Committee.  PIs are expected to seek regulatory approvals in a timely manner because project periods will not be extended. Note that the funding cannot be released until institutional review board (IRB) approval is obtained and copies sent to the cancer center’s administrative office. The UI Cancer Center Clinical Trials Office will assist with obtaining all required regulatory approvals. All publications derived from this funding must acknowledge cancer center support, such as:

This (work/research/project) was supported by the University of Illinois Cancer Center (UICC-DFA-994000) Program.  

The authors gratefully acknowledge use of the services and facilities of the Translational Pathology Core of the University of Illinois Cancer Center (UICC-DFA-994000).